Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda"
- PMID: 32800586
- DOI: 10.1016/j.jhep.2020.07.003
Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda"
Conflict of interest statement
Conflicts of interest Amit G. Singal has served on advisory boards and/or consultant for Bayer, Eisai, Genentech, Exelixis, Bristol Meyers Squibb, Astra-Zeneca, Wako Diagnostics, Glycotest, Exact Sciences, Roche, and TARGET Pharmasolutions. He has received research funding from Gilead. Pietro Lampertico has served on advisory boards, consultant, or speakers bureau for BMS, Roche, Gilead, GSK, Abbvie, MSD, Arrowhead, Alnylam, Janssen, Spring Bank, MYR, Eiger, and Alfasigma. Pierre Nahon has received honoraria from and/or consults for Abbvie, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Gilead, Ipsen and MSD. He received research grants from Abbvie and Bristol-Myers Squibb. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Epidemiology and surveillance for hepatocellular carcinoma: New trends.J Hepatol. 2020 Feb;72(2):250-261. doi: 10.1016/j.jhep.2019.08.025. J Hepatol. 2020. PMID: 31954490 Free PMC article. Review.
-
Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda.J Hepatol. 2020 Nov;73(5):1271-1273. doi: 10.1016/j.jhep.2020.05.045. Epub 2020 Aug 14. J Hepatol. 2020. PMID: 32800587 No abstract available.
